Free Trial
NASDAQ:ETON

Eton Pharmaceuticals (ETON) Stock Price, News & Analysis

Eton Pharmaceuticals logo
$19.60 +0.03 (+0.15%)
Closing price 05/20/2025 04:00 PM Eastern
Extended Trading
$19.74 +0.13 (+0.69%)
As of 08:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Eton Pharmaceuticals Stock (NASDAQ:ETON)

Key Stats

Today's Range
$19.38
$19.93
50-Day Range
$11.47
$19.70
52-Week Range
$3.18
$21.48
Volume
162,848 shs
Average Volume
192,227 shs
Market Capitalization
$525.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.00
Consensus Rating
Buy

Company Overview

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Eton Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

ETON MarketRank™: 

Eton Pharmaceuticals scored higher than 48% of companies evaluated by MarketBeat, and ranked 557th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Eton Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Eton Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Eton Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Eton Pharmaceuticals are expected to grow in the coming year, from ($0.14) to $0.50 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Eton Pharmaceuticals is -89.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Eton Pharmaceuticals is -89.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Eton Pharmaceuticals has a P/B Ratio of 32.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.62% of the outstanding shares of Eton Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Eton Pharmaceuticals has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eton Pharmaceuticals has recently increased by 74.49%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Eton Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Eton Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.62% of the outstanding shares of Eton Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Eton Pharmaceuticals has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eton Pharmaceuticals has recently increased by 74.49%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Eton Pharmaceuticals has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 26 news articles for Eton Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    13 people have searched for ETON on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Eton Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Eton Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.03% of the stock of Eton Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 27.86% of the stock of Eton Pharmaceuticals is held by institutions.

  • Read more about Eton Pharmaceuticals' insider trading history.
Receive ETON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ETON Stock News Headlines

Eton Pharmaceuticals Set To Dominate Orphan Drug Niche
B. Riley Issues Pessimistic Forecast for ETON Earnings
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
Eton Pharmaceuticals' (ETON) Buy Rating Reiterated at B. Riley
HC Wainwright Has Negative Outlook of ETON Q2 Earnings
See More Headlines

ETON Stock Analysis - Frequently Asked Questions

Eton Pharmaceuticals' stock was trading at $13.32 at the beginning of 2025. Since then, ETON shares have increased by 47.1% and is now trading at $19.60.
View the best growth stocks for 2025 here
.

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) posted its quarterly earnings data on Tuesday, May, 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.09 by $0.02. The company earned $17.28 million during the quarter, compared to analyst estimates of $14.33 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative trailing twelve-month return on equity of 36.29%.
Read the conference call transcript
.

Eton Pharmaceuticals (ETON) raised $22 million in an initial public offering on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation acted as the underwriter for the IPO.

Top institutional shareholders of Eton Pharmaceuticals include Nantahala Capital Management LLC (4.38%), Westside Investment Management Inc. (1.84%), Millennium Management LLC (1.33%) and Connor Clark & Lunn Investment Management Ltd. (0.87%). Insiders that own company stock include Opaleye Management Inc and Sean Brynjelsen.
View institutional ownership trends
.

Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eton Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Arista Networks (ANET), CrowdStrike (CRWD) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
5/13/2025
Today
5/20/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ETON
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$29.00
High Stock Price Target
$33.00
Low Stock Price Target
$26.00
Potential Upside/Downside
+48.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-940,000.00
Pretax Margin
-15.30%

Debt

Sales & Book Value

Annual Sales
$48.33 million
Cash Flow
$0.00 per share
Price / Cash Flow
4,502.79
Book Value
$0.60 per share
Price / Book
32.67

Miscellaneous

Free Float
22,172,000
Market Cap
$525.63 million
Optionable
Optionable
Beta
1.22
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:ETON) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners